Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedDeficit | AccumulatedOtherComprehensiveLoss | Non-ControllingInterest | TotalStockholders’Equity | |
| Balance as of December 31, 2020 | 1,288,596 | $129 | $929,125 | $(467,878) | $— | $8,676 | $470,052 |
| Issuance of common stock upon exercise or vesting of equity awards | 91,080 | 9 | 167 | — | — | — | 176 |
| Vesting of restricted stock - earnouts | 38,799 | 4 | (4) | — | — | — | — |
| Tax withholdings related to net share settlement of equity awards | (797) | — | (9,463) | — | — | — | (9,463) |
| Founder shares repurchase | (2,707) | — | (24,998) | — | — | — | (24,998) |
| Issuance of warrants to purchase Series D convertible preferred stock | — | — | 300 | — | — | — | 300 |
| Issuance of Series D and B convertible preferred stock upon exercise of warrants | 1,014 | — | — | — | — | — | — |
| Issuance of Series E convertible preferred stock in exchange for warrants | 408 | — | — | — | — | — | — |
| Issuance of common stock for a business acquisition | 1,634 | — | 15,160 | — | — | — | 15,160 |
| Issuance of common stock upon reverse recapitalization, net of offering costs (Note 3) | 193,366 | 19 | 1,509,610 | — | — | — | 1,509,629 |
| Assumption of Public and Private Placement Warrants | — | — | (194,453) | — | — | — | (194,453) |
| Contributions from non-controlling interests | — | — | — | — | — | 59,933 | 59,933 |
| Stock-based compensation expense | — | — | 1,579,400 | — | — | — | 1,579,400 |
| Foreign currency translation | — | — | — | — | (1,715) | — | (1,715) |
| Net loss | — | — | — | (1,830,047) | — | (6,595) | (1,836,642) |
| Balance as of December 31, 2021 | 1,611,393 | 161 | 3,804,844 | (2,297,925) | (1,715) | 62,014 | 1,567,379 |
| Issuance of common stock upon exercise or vesting of equity awards | 124,651 | 13 | 239 | — | — | — | 252 |
| Tax withholdings related to net share settlement of equity awards | (296) | — | (981) | — | — | — | (981) |
| Issuance of common stock for business and asset acquisitions, net of issuance costs | 114,517 | 12 | 279,733 | — | — | — | 279,745 |
| Issuance of common stock pursuant to public offering, net of issuance costs | 41,384 | 4 | 98,906 | — | — | — | 98,910 |
| Issuance of common stock in exchange for services | 327 | — | 1,000 | — | — | — | 1,000 |
| Deconsolidation of subsidiaries | — | — | — | — | — | (55,408) | (55,408) |
| Acquisition of non-controlling interests | — | — | 7,390 | — | — | (7,390) | — |
| Adoption of ASC 842 | — | — | — | 5,195 | — | — | 5,195 |
Consolidated Statements of Stockholders’ Equity
| Common Stock | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedDeficit | AccumulatedOtherComprehensiveLoss | Non-ControllingInterest | TotalStockholders’Equity | |
| Stock-based compensation expense | — | — | 1,945,247 | — | — | 2,227 | 1,947,474 |
| Foreign currency translation | — | — | — | — | (917) | — | (917) |
| Net loss | — | — | — | (2,104,929) | — | (1,443) | (2,106,372) |
| Balance as of December 31, 2022 | 1,891,976 | 190 | 6,136,378 | (4,397,659) | (2,632) | — | 1,736,277 |
| Issuance of common stock upon exercise or vesting of equity awards | 98,767 | 9 | 546 | — | — | — | 555 |
| Tax withholdings related to net share settlement of equity awards | (14) | — | (23) | — | — | — | (23) |
| Settlement of contingent consideration | 3,848 | — | 8,896 | — | — | — | 8,896 |
| Issuance of common stock for asset acquisitions | 4,771 | — | 6,820 | — | — | — | 6,820 |
| Issuance of common stock in exchange for services | 2,023 | — | 2,500 | — | — | — | 2,500 |
| Forfeiture of restricted stock | (56) | — | — | — | — | — | — |
| Stock-based compensation expense and other | — | — | 230,880 | — | — | — | 230,880 |
| Foreign currency translation | — | — | — | — | 4,116 | — | 4,116 |
| Net loss | — | — | — | (892,869) | — | — | (892,869) |
| Balance as of December 31, 2023 | 2,001,315 | $199 | $6,385,997 | $(5,290,528) | $1,484 | $— | $1,097,152 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.